SEMINARS IN wh. PERINATOLOGY ELSEVIER eee SSS AUTHOR INDEX SUBJECT INDEX \ase syndrom Abdon ABO blood pT Abortion cx ACE inhibitors Actinetobacter s SEMINARS IN wh. PERINATOLOGY ELSEVIER eee SSS AUTHOR INDEX SUBJECT INDEX \ase syndrom Abdon ABO blood pT Abortion cx ACE inhibitors Actinetobacter s Subject Index Subject Index _ OeaIIEEEEEE——— —————————————————————— el andins, for neonatal Candida infe preeclampsia recurrence for HIV-1, 1 infant lorm for VLBW pregnal FDA risk categories for, 364 ulation and fetal metabolism of, 364-365 Subject Index nprreeognn ancy> " 12) 0-121 7? reduction strategies for, Subject Index and, 84-85 abnormalities ntrauterine likelihood Intravenous cannulation Intravenous immunoglobulin (IVIG), for adverse p vention, 210 Itraconazole,] for n> eonat> al Candriidda iin nfections,> 4j 1 lUDs (intrauterine devices), for transplant recipients, 37 IUGR. See Intrauterine growth restriction Subject Index Subject Index pathology in, 206 RA (rheumatoid arth perinatal HIV infection interventions Radiation exposure, advet pulmonary functions in Rapid test, for HIV-1, 113 a= = S &S s % 386 Subject Index [opical anesthetics, 323-328 (Continued) Ureapnilaa sma 1 ureaall yticum, . 2, .5 for peripherally inserted central catheters Uterine artery Doppler studies for venipuncture or arterial puncture, 324-325 in adverse pregnancy outcome prediction, 209-210 Total blood volume, of preterm infants, 102 elfect ol gestational age on, 2 33-235 lotal parenteral nutrition (TPN) in evaluating FGR risk, 131 for short bowel syndrome, 105-107 in first trimester, 235 usage guidelines, 69 in prediction of preeclampsia, 235-236 [race minerals, for parental nutrition, 106-107 terine artery embolization, recurrent postpartum hemorrh Tracheal intubation terine invasion, recurrent postpartum hemorrhage and adverse physiological effects, 312 teroplacental circulation premedication, 309-316 multigate spectral Doppler analysis of, 237-238 regimens, comparison of, 313- qualitative and semi-quantitative assessment of use in clinical practice, 312 quantitative assessment of, 232)- 236 vs. awake intubation, 310-311 teroplacental interface, adverse pregnat Transdermal contraceptive patch (Ortho Evra®), for transplant recipients /D Vaginal ring (NuvaRing® lransfusion-associated graft versus host disease (TA-GVHD), 265 ancomycin-resistant enterococ [ransfusions, perinatal. See Blood product replacement, in perinatal period ascular disease, maternal, fetal grow Transfusion-transmitted diseases, risk reduction, 265 enipuncture, topical anesthesia for Transplant recipients enous thromboembolism contraception tor entilated neonates, routine female, prevalence of ery low birth weight infants immunosuppressive therapy for (See Immunosupopressive drugs) iniants [riazoles, for neonatal Candida infections, 41 lriploidy, fetal growth restriction and, 126 rophic feedings, vs. enteral feedings, 63-64 lrophoblast, differentiation/invasion, 205-20( [Tumor necrosis factor-a, +, 205 [win gestation, recurrent spontaneous preterm birth a1 rasound assessmet circulaulor queae litativbe e anad qu ant! qualitative d semi-quantitative quantlative, 2 Uniparental disomy) United Kingdom United States cliiaapbdeetteess pprre \ psrreevvaa le 4 rBePdpDl asdmedv elIontp n chorioamnionitis and congenital neot and future BPD resear as NL, uman di| s in inflammati premature treatment